CA2068567A1 - Amide esters of rapamycin - Google Patents
Amide esters of rapamycinInfo
- Publication number
- CA2068567A1 CA2068567A1 CA002068567A CA2068567A CA2068567A1 CA 2068567 A1 CA2068567 A1 CA 2068567A1 CA 002068567 A CA002068567 A CA 002068567A CA 2068567 A CA2068567 A CA 2068567A CA 2068567 A1 CA2068567 A1 CA 2068567A1
- Authority
- CA
- Canada
- Prior art keywords
- carbon atoms
- alkyl
- hydrogen
- rapamycin
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
ABSTRACT
A compound of the structure wherein R1 and R2 are each independently, hydrogen or ;
X is -(CH2)m- or -Ar-; R3 and R4 are each, independently, hydrogen, alkyl, -(CH2)n-Ar, -(CH2)p-NR5R6, or-(CH2)p-N+R5R6R7Y-; R5 and R6 are each, independently, hydrogen, alkyl, or -(CH2)n-Ar; Ar is an optionally substituted group selected from , , , , , ,or
A compound of the structure wherein R1 and R2 are each independently, hydrogen or ;
X is -(CH2)m- or -Ar-; R3 and R4 are each, independently, hydrogen, alkyl, -(CH2)n-Ar, -(CH2)p-NR5R6, or-(CH2)p-N+R5R6R7Y-; R5 and R6 are each, independently, hydrogen, alkyl, or -(CH2)n-Ar; Ar is an optionally substituted group selected from , , , , , ,or
Description
2~6g~7 S BACKGROUND OF THE ]NVENTION
This invention relates to amide esters of raparnycin and a method for using themin the treatment of transplantation rejection, host vs. graft disease, autoimmune diseases, diseases of inflammation, solid tumors, and fungal infections.
Rapamycin is a macrocyclic triene antibiotic produced by Streptomvces hy~roscopicus, which was found to have antifungal activity, particularly againstCandida albicans, both in vitro and in vivo [C. Vezina et al., J. Antibiot. 28, 721 (1975); S.N. Sehgal et al., J. Antibiot. 28, 727 (1975); H. A. Baker et al., J. Antibiot.
31, 539 (1978); U.S. Patenl 3,929,992; and U.S. Patent 3,993,749].
Rapamycin alone (lJ.S. Patent 4,885,171) or in combination with picibanil (U.S. Patent 4,401,653) has been shown to have antitumor activity. R. Martel et al.
[Can. J. Physiol. Pharmacol. 55, 48 (1977)] disclosed that rapamycin is effective in the experimental allergic encephalomyelitis model, a model for multiple sclerosis; in the adjuvant arthritis model, a model for rheumatoid arthritis; and effectively inhibited the 20 formation of IgE-like antibodies.
The immunosuppressive effects of rapamycin have been disclosed in FASEB 3, 3411 (1989). Cyclosporin A and FK-506, other macrocyclic molecules, also have been shown to be effective as immunosuppressive agents, therefore useful in preventing transplant rejection lFASEB 3, 3411 (1989); FASEB 3, 5256 (1989); and R. Y. Calne et al., Lancet 1] 83 (1978)].
Mono- and diacylated derivatives of rapamycin (esterified at the 28 and 43 positions) have been shown to be useful as antifungal agents (U.S. Patent 4,316,885) and used to make water soluble prodrugs of rapamycin (U.S. Patent 4,650,803).
Recently, the numbering convention for rapamycin has been changed; therefore according to Chemical Abstracts nomenclature, the esters described above would be at the 31- and 42- positions.
, 2068~67 DESCRIPTION OF THE INVENTION
This invention provides derivatives of rapamycin which are` useful as immunosuppressive, anti-inflammatory, antifungal, and antitumor agents having the structure ~OR
r' ~~" OMe ~ --I~R2 HO~
O OMe ~`~~
O O
wherein R1 and R2 are each independently, hydrogen or -C-X-C-NR3R4;
X is -(CH2)m- or -Ar-;
R3 and R4 are each, independently, hydrogen, alkyl of 1-12 carbon atoms, -(CH2)n-Ar, -(CH2)p-NR5R6, or -(CH2)p-N+R5R6R7Y
R5 and R6 are each, independently, hydrogen, alkyl of 1-12 carbon atoms, or -(CH2)n-Ar;
Ar is an optionally mono- or di- substituted group selected from 0~ -~. ~.
R7~ Y ~ , or ~
20~8567 AHP-g776 in which the optional substituents are selected from the group consisting of alkyl of 1-6 carbon atoms, araLI~yl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, or perfluoroalkyl of 1-6 carbon atoms;
5 R7 is alkyl of 1-6 carbon atoms;
Y is a halide, sulfate, phosphate, or p-toluenesulfonate anion;
m= 1-6;
n = 1-6;
p = 1-6;
10 with the proviso that Rl and R2 are not both hydrogen;
or a pharmaceutically acceptable salt thereof.
Pharmaceutically acceptable salts may be formed when R3 or R4 is -(CH2)p-NRSR6 or when Ar is an optionally mono- or di- substituted pyridyl or 15 quinolyl group. The pharmaceutically acceptable salts are those derived from such organic and inorganic acids such as, acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and the like.
Of these compounds, preferred members are those in which X is -(CH2)m-;
those in which X is -(CH2),n- and R3 and R4 are alkyl of 1-6 carbon atoms; and those in which X is -(CH2)m-, R3 is hydrogen, and R4 is and Ar is -(CH2)n-Ar.
The compounds of this invention acylated at the 42-position can be prepared by acylating rapamycin with an amido-acid acylating agent having the general structure O O
HOJ~ X J~ NR3R4 in the presence of a coupling reagent, such as a suitably substituted carbodiimide coupling reagent.
The compounds of this invention acylated at both the 31- and 42-positions can be prepared by the method described above by increasing variables such as reaction dme, temperature, and quantity of acylating agent .
The 31-acylated compounds of this invendon can be prepared by protecting the 42-alcohol of rapamycin with a protecting group, such as with a tert-butyl dimethylsilyl .
2~8~67 group in the presence of a base, such as imidazole, followed by acylation of the31-position with an acylating agent having the general structure shown above.
Removal of the protecting group provides the 31-acylated compounds. In the case of the tert-butyl dimethylsilyl protecting group, deprotection can be accomplished under 5 mildly acidic conditions, such as with a mixture of aqueous acetic acid and THF.
Having the 31-position acylated and the 42-position deprotected, the 42-position can be reacted with a different amido-acid of the generic structure described above than was reacted witll the 31-alcohol, to give compounds having different acyl moieties at the 31- and 42- positions. Al$ernatively, the 42-acyl compounds, prepared 10 as described above, can be reacted with an acylating agent having a different structure to provide compounds having different acyl moieties at the 31- and 42-positions.The acylating groups used to prepare the compounds of the invention are can be prepared by the method outlined below from anhydrides that are either commercially available or by methods that are that are disclosed in the literature.
o R3R4NH J~ O
X - ~ HO X NR3R4 o Immunosuppressive activity was evaluated in an ~ vitro standard pharmacological test procedure to measwre Iymphocyte proliferation (I,AF) and in two in ~_ standard pharrnacological test procedures. The first in vivo procedure was a 20 popliteal Iymph node (PLN) test procedure which measured the effect of compounds of this invention on a mixed Iymphocyte reaction and the second in vivo procedure evaluated the survival time of a pinch skin graft.
The comitogen-induced thymocyte proliferation procedure (LAF) was used as an in VitrQ measure of the immunosuppressive effects of representative compounds.
25 Briefly, cells from the thymus of normal BALB/c mice are cultured for 72 hours with PHA and IL-l and pulsed with tritiated thymidine durin~ the last six hours. Cells are cwltured with and without various concentrations of rapamycin, cyclosporin A, or test compound. Cells are harvested and incorporated radioactivity is determined. Inhibition of Iymphoproliferation is assessed as percent change in counts per minute from non-30 drug treated controls. The results are expressed by the following ratio.
- 2~8~67 \
3H-control thvmus cells - H3-ra~amvcin-treated thvmus cells 3H-control thymus cells - H3-test compound-treated cells A mixed Iymphocyte reaction (MLR) occurs when Iymphoid cells frorn 5 genetically distinct animals are combined in tissue culture. Each stimulates the other to undergo blast transformation which results in increased DNA synthesis that can be quantified by the incorporation of tritiated thymidine. Since stimulating a MLR is a function of disparity at Major Histocompatibility antigens, an in vivo popliteal Iyrnph node (PLN) test procedure closely correlates to host vs. graft disease. Briefly,10 irradiated spleen cells from BALB/c donors are injected into the right hind foot pad of recipient C3H mice. The drug is given daily, p.o. from Day 0 to Day 4. On Day 3 and Day 4, tritiated thymidine is given i.p., b.i.d. On Day 5, the hind popliteal Iymph nodes are removed and dissolved, and radioactivity counted. The corresponding left PLN serves as the control for the PLN from the injected hind foot. Percent 15 suppression is calculated using the non-drug treated animals as allogenic control.
Rapamycin at a dose of 6 mg/kg, p.o. gave 86% suppression, whereas cyclosporin Aat the same dose gave 43% suppression. Results are expressed by the following ratio:
3H-PLN cells control C3H mouse - 3H-PLN cells rapamvcin-treated C3H mouse 2û 3H-PLN cells control C3H mouse - 3H-Pl,N cells test compound-treated C3H mouse The second in~ vivo test procedure is designed to determine the survival time ofpinch skin graft from male DBA/2 donors transplanted to male BALB/c recipients. The method is adapted from Billingham R.E. and Medawar P.B., J. Exp. ~iol. 28:385-25 402, (1951). Briefly, a pinch skin graft from the donor is grafted on the dorsum of the recipient as a homograft, and an autograft is used as control in the same region. The recipients are treated with either varying concentrations of cyclosporin A as test control or the test compound, intraperitoneally. Untreated recipients serve as rejection control.
The graft is monitored daily and observations are recorded until the graft becomes dry 30 and forms a blackened scab. This is considered as the rejection day. The mean graft survival time (number of days + S.D.) of the drug treatment group is compared with the control group.
The following table summarizes the results of representative compounds of this invention in these three standard test procedures.
: :
., . :
~ 0 ~ 7 L A F PLNSkin Graft Compound (ratio) (ratio)(davs + SD) Example 1 1.94 0.62 +
Example2 0.14 + +
Example3 0.19 1~.767.5 + 1.5 Example4 0.91 0.599.5 + 0.8 Rapamycin 1.00 1.0012.0 + 1.7 + Not evaluated.
The results of these standard pharmacological test procedures demonstrate 15 immunosuppressive activity both in vitro and in vivo for the compounds of this invention. Positive ratios in the LAF and PLN test procedures indicate suppression of T cell proliferation. As a transplanted pinch skin grafts are typically rejected within ~7 days without the use of an irnmunosuppressive agent, the increased survival time of the skin graft when treated with the compounds of this invention further demonstrates their 20 utility as immunosuppressive agents.
Because the compounds of this invention are structurally similar to rapamycin and have a similar activity profile to rapamycin, the compounds of this invention also are considered to have antitumor and antifungal activities.
Based on the results of these standard pharmacological test procedures, the 25 compounds are useful in the treatment of transplantation rejection such as, heart, kidney, liver, bone marrow, and skin transplants; autoimmune diseases such as, lupus, rheumatoid arthritis, diabetes mellitus, myasthenia gravis, and multiple sclerosis; and diseases of inflammation such as, psoriasis, dermatitis, eczema, seborrhea, inflarnmatory bowel disease. and eye uveitis; solid tumors; and fungal infections.
The compounds may be administered neat or with a pharmaceutical catTier to a mammal in need thereof. The pharmaceutical carrier may be solid or liquid.
A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, 35 compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier 2 06 8 ~ 6 7 having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl S cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic 10 solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially 15 containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethy] oleate and isopropyl myristate. Sterile liquid carriers are useful 20 in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellent.
Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous 25 injection. Sterile solutions can also be administered intravenously. The cormpound can also be administered orally either in liquid or solid composition form.
Preferably, the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be 30 packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. The dosage to be used in the treatment must be subjectively determined by the attending physician.
.
.
2Q68~67 In addition, the compounds of this invention may be employed as a solution, cream, or lotion by formulation with phaTmaceutically acceptable vehicles containing 0.1 - 5 percent, preferably 2%, of active compound which may be administered to a fungally affected area.
s The following examples illustrate the preparation of representative compounds of this invention.
~:xample 1 Rapamvcin 42-ester with 4-(dimethylarnino~-4-oxobutanoic acid To a solution of 1.00 g (1.09 mmol) of rapamycin in 20 mL of dry dichloromethane was added 316 mg (2.18 mmol) of N, N-dimethylsuccinamic acid, 15 mg of 4- N,N-dimethylaminopyridine followed by 476 mg (mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. The solution was stirredovernight and then poured into 1 N HCI and extracted three times with ethyl acetate.
The organic layers were combined, washed with brine, dried over anhydrous sodiumsulfate, filtered, and concentrated in vacuo to give a pale yellow foamy solid. The residue was flash chromatographed on a 40 mm x 150 mm silica column eluting with40-60 % ethyl acetate/hexane to give 105 mg (10 %) of pure rapamycin 42-ester with 4-(dimethylamino)-4-oxobutanoic acid, which was isolated as the monohydrate. The spectral data follows: lH NMR (CDC13, 400 MHz) ~ 4.81 (s, 1 H, anomeric OH), 4.66 (m, 1 H, -CHO2CCH~), 4.19 (m, 1 H, 31-CHOH), 3.39 ~s, 3 H, -OCH3), 3.33 (s, 3 H, -OCH3), 3.14 (s, 3 H, -OCH3), 3.03 (s, 3 H, -CONCH3), 2.95 (s, 3 H, -CONC'H3), 2.67 (m, 4 H, -O2CCH2CH2CONMe2), 1.75 (s, 3 H7 CH3C=C-), 1.65 (s, 3 H, CH3C=C-); IR (KBr) 3450 (OH), 2940, 2890, 1735 (C=O), 1650 (C=O), 1455, 1380, 1295, 1105, 995 cm~]; MS (neg. ion FAB) 1040 (M-); MS Peak Matching (neg.
ion FAB) calcd for 1040.61842, found 1040.6196.
AnalysisCalcdforCs7H88N2Ol5 C 65.74; H 8.52; N 2.69 Found C 65.81; H 8.73; N 2.42 2068~6~
The following representative compounds can be prepared from rapamycin and the appropriate amido-ester by employing the method used to prepare the title compound in Example 1.
s Rapamycin-42-ester with 4-l [1-(4-chlorophenyl)methyl]amino]-4-oxobutanoic acid Rapamycin-42-ester with 5-l [3-(2-naphthyl)propyl]amino]-S-oxopentanoic acid Rapamycin-42-ester with ~(N-methyl-N-hexylamino)-~oxohexanoic acid Rapamycin-42-ester with ~l [3-(dimethylamino)propyl]amino]-4-oxobutanoic acid Rapamycin-42-ester with 5-l[4-(octylamino)butyl]amino]-5-oxopentanoic acid Rapamycin-42-ester with 4-l [2-(3-(~hydroxyquinolyl))ethyl~amino]-4-oxobutanoic acid Rapamycin-42-ester with 4-l [2-(phenylmethylamino)ethyl]amino]-4-oxobutanoic acid lS Rapamycin-42-ester with S-(N-hexyl-N-decylamino)-S-oxopentanoic acid Rapamycin-42-ester with 2-(dimethylcarbamyl) benzoic acid Rapamycin-42-ester with 2-l [3-(diethylamino)propyl]carbamyl] benzoic acid Rapamycin-42-ester with 2-l(phenylmethyl)carbamyl] nicotinic acid Rapamycin-42-ester with 3-l(phenylmethyl)carbamyl] picolinic acid Example 2 Rapamvcin 31~42-diester with ~oxo-4-r~2-(2-pvridinvl)ethvllaminolbutanoic acid To a solution of 5.0 g (50 mmol) of succinic anhydride in 50 mL of dichloromethane was added 550 mg of DMAP and 6.1 g (50 mmol) of 2-~2'-aminoethyl)pyridine. An exothermic reaction resulted. The reaction was refluxed for 1 h and cooled to room temp~rature and stirred for 48 h. The reaction is worked up by concentrated in vacuo: the ~esulting solid was dissolved in pH 4 buffer and extracted three times with 4: 1 ethyl acetate/tetrahydrofuran after the aqueous solution had been saturated with ammonium sulfate. The organic layer was dried over sodium sulfate and concentrated in vacuo to ~ive a residue. The residue was recrystallized from ethyl acetate/methanol to give 5.5 g (S0 %) of 4-oxo-4-[[2-(2-pyridinyl)ethyl]amino]butanoic acid.
To a solution of 3.8 g (4.19 mmol) of rapamycin in 125 mL of dichloromethane was added at room tempera~ure, 200 mg of DMAP,4.3 g (20.9 mmol) of dicyclohexyl-carbodiimide and 4.6 g (20.7 mmol) of 4-oxo-4-[[2-(2-pyridinyl)ethyl]amino]butanoic acid. The reaction was stirred overnight at room temperature. The reaction mixture was poured into water and extracted twice with ethyl acetate. The combined organic extracts were dried over sodium sullate and concentrated in vacuo to give a solid residue. The residue was purified by preparative HPLC (Waters Prep 501), 5 % methanol/ethyl ~X5~7 acetate) to give 4.30 g (79 %) of pure rapamycin 31,42-ester with 4-oxo-4-[[2-(2-pyridinyl)-ethyl]amino]butanoic acid.
The spectral data follows: lH NMR (CDC13, 400 MHz) o 8.53 (s, 1 H, arom), 7.67 (m, 1 H, arom), 7.22 (m, 2 H, arom), 6.74 (m, 1 H, arom), 4.63 (m, 1 H, -CHO2CCH2), 4.18 (m, 1 H, 31-CHOH), 3.68 (m, 2 H, -CONHCH2), 3.36 (s, 3 H, -OCH3), 3.35 (s, 3 H, -OCH3), 3.14 (s, 3 H, -OCH3), 3.02 (m, 2 H, CH2Pyr), 2.67 (s, 3 ~1, -02CCH2CH2CONHR), 1.75 (s, 3 H, CH3C=C-), 1.66 (s, 3 H, CH3C=C-);
IR (KBr) 3390 (OH), 2930, 2850, 1735 (C=O), 1640 (C=O), 1535, 1455, 1380, 1295, 1100, 995 cm-l; MS (neg. FAB) 1321 (M-).
The following representative compounds can be prepared from rapamycin and the appropriate arnido-ester by employing the method used to prepare the title compound in Example 2.
Rapamycin-31,42-diester with 4-[[1-(4-chlorophenyl)methyl]amino]-4-oxobutanoic acid Rapamycin-31,42-diester with 6-(N-methyl-N-hexylamino)-6-oxohexanoic acid Rapamycin-31,42-diester with 4-[[3-(dimethylamino)propyl]amino]-4Oxobutanoic acid Rapamycin-31,42-diester with 5-[[4-(octylamino)butyl]amino]-5-oxopentanoic acid Rapamycin-31,42-diester with 4-[[2-(3-(6-hydroxyquinolyl))ethyl]amino]-4-oxobutanoic acid Rapamycin-31,42-diester with 4-[[2-(phenylmethylamino)ethyl]amino]-4Oxobutanoic acid Rapamycin-31,42-diester with 4-[~2-(2-indolyl)ethyl]amino]-4-oxobutanoic acid Rapamycin-31,42-diester with 5-(N-hexyl-N-decylamino)-5-oxopentanoic acid Rapamycin-31,42-diester with 2-(dimethylcarbamyl) benzoic acid Rapamycin-31,42-diester with 2-1[3-(diethylamino)propyl]carbamyl] benzoic acid Example 3 Rapamycin 31.42-diester with 4-oxo-4-ir2-(2-pYridinvl)ethvllaminol butanoic acid dihvdrochlorid~
To a solution of Sû0 mg (37811mol) of rapamycin 31,42-ester with 4-oxo-4-[[2-(2-pyridinyl)ethyl]amino]butanoic acid in 2 mL of methanol was added 5~ ',lL of acetyl chloride. The reaction mixture is concentrated in vacuo to give 530 mg (100 %) of pure 20~8a67 rapamycin 31,42-ester with 4-oxo-4-[[2-(2-pyridinyl3ethyl]amino]butanoic acid dihydrochloride .
The spec~al data follows: lH NMR (d6-DMSO, ~00 MHz) â 8.53 ~s, 1 H, arom), 8.32 (m, 1 H, arom), 7.76 (m, 2 H, arom), 8.06 (m, 1 H, arom), 3.45 (m, 5 H, -S OCH3 and -CONHCH2), 3.44 (s, 3 H, -OC1~3), 3.23 Is, 3 H, -OCH3), 3.07 (m, 2 H, CH2Pyr), 2.49 (s, 3 H, -O2CCH2CH2CONHR), 1.79 (s, 3 H, CH3C=C-), 1.66 (s, 3 H, CH3C=C-); IR (KBr) 3400 (OH), 2920, 2850, 1735 (C=O), 1635 (C=O), 1545, 144~, 1370, 1150, 985 cm~l; MS (neg. FAB) calculated for C73H113N5O17 1321.8950, found 1321.7350; MS (neg. FAB~ 1321 (free base, M-), 590, 446 (100), 297.
AnalysisCalcdforC73HIlsNsOl7Cl2 5H2O C 56.04; H 6.71; N 4.47 Found C 55.66; H 6.36; N 4.29 Example 4 .
Rapamvcin 31.42-diester with 2-r2-1 (3-carboxy- 1 -oxopropvl)aminolethyll - 1 -methyl-~yridinium iodide To a solution of 500 mg (378 llmol) of rapamycin 31,42-ester with 4-oxo-4-~[2-(2-pyridinyl)ethyl]amino]butanoic acid in 2 mL of acetone was added 50 ~lL of methyl iodide and the reaction was stirred overnight at room temperature. The reaction was incomplete so 25 ',lL of methyl iodide was added and refluxed. The reac~ion mixture was cooled to room temperature and concentrated in vacuo to give 580 mg (98 %) of rapamycin 31,42-ester with 2-[2-[(3-carboxy-1-oxopropyl)amino]ethyl]-1-methylpyridinium iodide, which was isolated as the tetrahydrate.
The spectral data follows: IH NMR (CDC13, 400 MHz) ~ 9.05 (m, 1 H, arom), 8.40 (m, 1 H, arom), 8.04 (m, 1 H, arom), 7.89 (m, 2 H, arom), 4.53 (s, 3 H, NCH3+), 3.64 (m, 2 H, -CONHCH2), 3.38 (s, 3 H, -OCH3), 3.33 (s, 3 H, -OCH3), 3.12 (s, 3 H, -OCH3), 3.09 (m, 2 H, CH2Pyr), 2.56 (s, 3 H, -02CCH2CH2CONHR), 1.82 (s, 3 H, CH3C=C-), 1.64 (s, 3 1~, CH3C=C-); IR (KBr) 3410 (OH), 2920, 2840, 1720 (C=O), 1625 (C=O), 1535, 1430, 1360, 1225, 1100, 985 cm-l; MS (neg. FAB) 1605 (M-)-AnalysisCalcdfor('7sHIogNsol7I2 4H2O C 53.67; H 6.97; N 4.17 Found C 53.96; H 6.83; N 3.72 ,~ 2068~g7 The following representative compounds can be prepared from an appropriately substituted rapamycin ester and an appropriately substituted alkylating agent byemploying the method used tO prepare the title compound in Example 4.
S Rapamycin-3 1 ,42-diester with 3-[(3-carboxy- 1 -oxopropyl)amino]propyl trimethyl ammonium iodide Rapamycin-31,42-diester with 3-[(3-carboxy-1-oxopropyl)amino]propyl trimethyl ammonium sulfate Rapamycin-3 1 ,42-diester wi th 3-[(3-carboxy- 1 -oxopropyl)amino]propyl trimethyl ammonium phosphate Rapamycin-31,42-diester with 3-[(3-carboxy-1-oxopropyl)amino]propyl trimethyl ammonium p-toluenesulfonate Rapamycin-31,42-diester with 3-[2-[(3-carboxy-1-oxopropyl)amino]ethyl]-1-methyl-quinolinium iodide~
This invention relates to amide esters of raparnycin and a method for using themin the treatment of transplantation rejection, host vs. graft disease, autoimmune diseases, diseases of inflammation, solid tumors, and fungal infections.
Rapamycin is a macrocyclic triene antibiotic produced by Streptomvces hy~roscopicus, which was found to have antifungal activity, particularly againstCandida albicans, both in vitro and in vivo [C. Vezina et al., J. Antibiot. 28, 721 (1975); S.N. Sehgal et al., J. Antibiot. 28, 727 (1975); H. A. Baker et al., J. Antibiot.
31, 539 (1978); U.S. Patenl 3,929,992; and U.S. Patent 3,993,749].
Rapamycin alone (lJ.S. Patent 4,885,171) or in combination with picibanil (U.S. Patent 4,401,653) has been shown to have antitumor activity. R. Martel et al.
[Can. J. Physiol. Pharmacol. 55, 48 (1977)] disclosed that rapamycin is effective in the experimental allergic encephalomyelitis model, a model for multiple sclerosis; in the adjuvant arthritis model, a model for rheumatoid arthritis; and effectively inhibited the 20 formation of IgE-like antibodies.
The immunosuppressive effects of rapamycin have been disclosed in FASEB 3, 3411 (1989). Cyclosporin A and FK-506, other macrocyclic molecules, also have been shown to be effective as immunosuppressive agents, therefore useful in preventing transplant rejection lFASEB 3, 3411 (1989); FASEB 3, 5256 (1989); and R. Y. Calne et al., Lancet 1] 83 (1978)].
Mono- and diacylated derivatives of rapamycin (esterified at the 28 and 43 positions) have been shown to be useful as antifungal agents (U.S. Patent 4,316,885) and used to make water soluble prodrugs of rapamycin (U.S. Patent 4,650,803).
Recently, the numbering convention for rapamycin has been changed; therefore according to Chemical Abstracts nomenclature, the esters described above would be at the 31- and 42- positions.
, 2068~67 DESCRIPTION OF THE INVENTION
This invention provides derivatives of rapamycin which are` useful as immunosuppressive, anti-inflammatory, antifungal, and antitumor agents having the structure ~OR
r' ~~" OMe ~ --I~R2 HO~
O OMe ~`~~
O O
wherein R1 and R2 are each independently, hydrogen or -C-X-C-NR3R4;
X is -(CH2)m- or -Ar-;
R3 and R4 are each, independently, hydrogen, alkyl of 1-12 carbon atoms, -(CH2)n-Ar, -(CH2)p-NR5R6, or -(CH2)p-N+R5R6R7Y
R5 and R6 are each, independently, hydrogen, alkyl of 1-12 carbon atoms, or -(CH2)n-Ar;
Ar is an optionally mono- or di- substituted group selected from 0~ -~. ~.
R7~ Y ~ , or ~
20~8567 AHP-g776 in which the optional substituents are selected from the group consisting of alkyl of 1-6 carbon atoms, araLI~yl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, or perfluoroalkyl of 1-6 carbon atoms;
5 R7 is alkyl of 1-6 carbon atoms;
Y is a halide, sulfate, phosphate, or p-toluenesulfonate anion;
m= 1-6;
n = 1-6;
p = 1-6;
10 with the proviso that Rl and R2 are not both hydrogen;
or a pharmaceutically acceptable salt thereof.
Pharmaceutically acceptable salts may be formed when R3 or R4 is -(CH2)p-NRSR6 or when Ar is an optionally mono- or di- substituted pyridyl or 15 quinolyl group. The pharmaceutically acceptable salts are those derived from such organic and inorganic acids such as, acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and the like.
Of these compounds, preferred members are those in which X is -(CH2)m-;
those in which X is -(CH2),n- and R3 and R4 are alkyl of 1-6 carbon atoms; and those in which X is -(CH2)m-, R3 is hydrogen, and R4 is and Ar is -(CH2)n-Ar.
The compounds of this invention acylated at the 42-position can be prepared by acylating rapamycin with an amido-acid acylating agent having the general structure O O
HOJ~ X J~ NR3R4 in the presence of a coupling reagent, such as a suitably substituted carbodiimide coupling reagent.
The compounds of this invention acylated at both the 31- and 42-positions can be prepared by the method described above by increasing variables such as reaction dme, temperature, and quantity of acylating agent .
The 31-acylated compounds of this invendon can be prepared by protecting the 42-alcohol of rapamycin with a protecting group, such as with a tert-butyl dimethylsilyl .
2~8~67 group in the presence of a base, such as imidazole, followed by acylation of the31-position with an acylating agent having the general structure shown above.
Removal of the protecting group provides the 31-acylated compounds. In the case of the tert-butyl dimethylsilyl protecting group, deprotection can be accomplished under 5 mildly acidic conditions, such as with a mixture of aqueous acetic acid and THF.
Having the 31-position acylated and the 42-position deprotected, the 42-position can be reacted with a different amido-acid of the generic structure described above than was reacted witll the 31-alcohol, to give compounds having different acyl moieties at the 31- and 42- positions. Al$ernatively, the 42-acyl compounds, prepared 10 as described above, can be reacted with an acylating agent having a different structure to provide compounds having different acyl moieties at the 31- and 42-positions.The acylating groups used to prepare the compounds of the invention are can be prepared by the method outlined below from anhydrides that are either commercially available or by methods that are that are disclosed in the literature.
o R3R4NH J~ O
X - ~ HO X NR3R4 o Immunosuppressive activity was evaluated in an ~ vitro standard pharmacological test procedure to measwre Iymphocyte proliferation (I,AF) and in two in ~_ standard pharrnacological test procedures. The first in vivo procedure was a 20 popliteal Iymph node (PLN) test procedure which measured the effect of compounds of this invention on a mixed Iymphocyte reaction and the second in vivo procedure evaluated the survival time of a pinch skin graft.
The comitogen-induced thymocyte proliferation procedure (LAF) was used as an in VitrQ measure of the immunosuppressive effects of representative compounds.
25 Briefly, cells from the thymus of normal BALB/c mice are cultured for 72 hours with PHA and IL-l and pulsed with tritiated thymidine durin~ the last six hours. Cells are cwltured with and without various concentrations of rapamycin, cyclosporin A, or test compound. Cells are harvested and incorporated radioactivity is determined. Inhibition of Iymphoproliferation is assessed as percent change in counts per minute from non-30 drug treated controls. The results are expressed by the following ratio.
- 2~8~67 \
3H-control thvmus cells - H3-ra~amvcin-treated thvmus cells 3H-control thymus cells - H3-test compound-treated cells A mixed Iymphocyte reaction (MLR) occurs when Iymphoid cells frorn 5 genetically distinct animals are combined in tissue culture. Each stimulates the other to undergo blast transformation which results in increased DNA synthesis that can be quantified by the incorporation of tritiated thymidine. Since stimulating a MLR is a function of disparity at Major Histocompatibility antigens, an in vivo popliteal Iyrnph node (PLN) test procedure closely correlates to host vs. graft disease. Briefly,10 irradiated spleen cells from BALB/c donors are injected into the right hind foot pad of recipient C3H mice. The drug is given daily, p.o. from Day 0 to Day 4. On Day 3 and Day 4, tritiated thymidine is given i.p., b.i.d. On Day 5, the hind popliteal Iymph nodes are removed and dissolved, and radioactivity counted. The corresponding left PLN serves as the control for the PLN from the injected hind foot. Percent 15 suppression is calculated using the non-drug treated animals as allogenic control.
Rapamycin at a dose of 6 mg/kg, p.o. gave 86% suppression, whereas cyclosporin Aat the same dose gave 43% suppression. Results are expressed by the following ratio:
3H-PLN cells control C3H mouse - 3H-PLN cells rapamvcin-treated C3H mouse 2û 3H-PLN cells control C3H mouse - 3H-Pl,N cells test compound-treated C3H mouse The second in~ vivo test procedure is designed to determine the survival time ofpinch skin graft from male DBA/2 donors transplanted to male BALB/c recipients. The method is adapted from Billingham R.E. and Medawar P.B., J. Exp. ~iol. 28:385-25 402, (1951). Briefly, a pinch skin graft from the donor is grafted on the dorsum of the recipient as a homograft, and an autograft is used as control in the same region. The recipients are treated with either varying concentrations of cyclosporin A as test control or the test compound, intraperitoneally. Untreated recipients serve as rejection control.
The graft is monitored daily and observations are recorded until the graft becomes dry 30 and forms a blackened scab. This is considered as the rejection day. The mean graft survival time (number of days + S.D.) of the drug treatment group is compared with the control group.
The following table summarizes the results of representative compounds of this invention in these three standard test procedures.
: :
., . :
~ 0 ~ 7 L A F PLNSkin Graft Compound (ratio) (ratio)(davs + SD) Example 1 1.94 0.62 +
Example2 0.14 + +
Example3 0.19 1~.767.5 + 1.5 Example4 0.91 0.599.5 + 0.8 Rapamycin 1.00 1.0012.0 + 1.7 + Not evaluated.
The results of these standard pharmacological test procedures demonstrate 15 immunosuppressive activity both in vitro and in vivo for the compounds of this invention. Positive ratios in the LAF and PLN test procedures indicate suppression of T cell proliferation. As a transplanted pinch skin grafts are typically rejected within ~7 days without the use of an irnmunosuppressive agent, the increased survival time of the skin graft when treated with the compounds of this invention further demonstrates their 20 utility as immunosuppressive agents.
Because the compounds of this invention are structurally similar to rapamycin and have a similar activity profile to rapamycin, the compounds of this invention also are considered to have antitumor and antifungal activities.
Based on the results of these standard pharmacological test procedures, the 25 compounds are useful in the treatment of transplantation rejection such as, heart, kidney, liver, bone marrow, and skin transplants; autoimmune diseases such as, lupus, rheumatoid arthritis, diabetes mellitus, myasthenia gravis, and multiple sclerosis; and diseases of inflammation such as, psoriasis, dermatitis, eczema, seborrhea, inflarnmatory bowel disease. and eye uveitis; solid tumors; and fungal infections.
The compounds may be administered neat or with a pharmaceutical catTier to a mammal in need thereof. The pharmaceutical carrier may be solid or liquid.
A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, 35 compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier 2 06 8 ~ 6 7 having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl S cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic 10 solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially 15 containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethy] oleate and isopropyl myristate. Sterile liquid carriers are useful 20 in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellent.
Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous 25 injection. Sterile solutions can also be administered intravenously. The cormpound can also be administered orally either in liquid or solid composition form.
Preferably, the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be 30 packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. The dosage to be used in the treatment must be subjectively determined by the attending physician.
.
.
2Q68~67 In addition, the compounds of this invention may be employed as a solution, cream, or lotion by formulation with phaTmaceutically acceptable vehicles containing 0.1 - 5 percent, preferably 2%, of active compound which may be administered to a fungally affected area.
s The following examples illustrate the preparation of representative compounds of this invention.
~:xample 1 Rapamvcin 42-ester with 4-(dimethylarnino~-4-oxobutanoic acid To a solution of 1.00 g (1.09 mmol) of rapamycin in 20 mL of dry dichloromethane was added 316 mg (2.18 mmol) of N, N-dimethylsuccinamic acid, 15 mg of 4- N,N-dimethylaminopyridine followed by 476 mg (mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. The solution was stirredovernight and then poured into 1 N HCI and extracted three times with ethyl acetate.
The organic layers were combined, washed with brine, dried over anhydrous sodiumsulfate, filtered, and concentrated in vacuo to give a pale yellow foamy solid. The residue was flash chromatographed on a 40 mm x 150 mm silica column eluting with40-60 % ethyl acetate/hexane to give 105 mg (10 %) of pure rapamycin 42-ester with 4-(dimethylamino)-4-oxobutanoic acid, which was isolated as the monohydrate. The spectral data follows: lH NMR (CDC13, 400 MHz) ~ 4.81 (s, 1 H, anomeric OH), 4.66 (m, 1 H, -CHO2CCH~), 4.19 (m, 1 H, 31-CHOH), 3.39 ~s, 3 H, -OCH3), 3.33 (s, 3 H, -OCH3), 3.14 (s, 3 H, -OCH3), 3.03 (s, 3 H, -CONCH3), 2.95 (s, 3 H, -CONC'H3), 2.67 (m, 4 H, -O2CCH2CH2CONMe2), 1.75 (s, 3 H7 CH3C=C-), 1.65 (s, 3 H, CH3C=C-); IR (KBr) 3450 (OH), 2940, 2890, 1735 (C=O), 1650 (C=O), 1455, 1380, 1295, 1105, 995 cm~]; MS (neg. ion FAB) 1040 (M-); MS Peak Matching (neg.
ion FAB) calcd for 1040.61842, found 1040.6196.
AnalysisCalcdforCs7H88N2Ol5 C 65.74; H 8.52; N 2.69 Found C 65.81; H 8.73; N 2.42 2068~6~
The following representative compounds can be prepared from rapamycin and the appropriate amido-ester by employing the method used to prepare the title compound in Example 1.
s Rapamycin-42-ester with 4-l [1-(4-chlorophenyl)methyl]amino]-4-oxobutanoic acid Rapamycin-42-ester with 5-l [3-(2-naphthyl)propyl]amino]-S-oxopentanoic acid Rapamycin-42-ester with ~(N-methyl-N-hexylamino)-~oxohexanoic acid Rapamycin-42-ester with ~l [3-(dimethylamino)propyl]amino]-4-oxobutanoic acid Rapamycin-42-ester with 5-l[4-(octylamino)butyl]amino]-5-oxopentanoic acid Rapamycin-42-ester with 4-l [2-(3-(~hydroxyquinolyl))ethyl~amino]-4-oxobutanoic acid Rapamycin-42-ester with 4-l [2-(phenylmethylamino)ethyl]amino]-4-oxobutanoic acid lS Rapamycin-42-ester with S-(N-hexyl-N-decylamino)-S-oxopentanoic acid Rapamycin-42-ester with 2-(dimethylcarbamyl) benzoic acid Rapamycin-42-ester with 2-l [3-(diethylamino)propyl]carbamyl] benzoic acid Rapamycin-42-ester with 2-l(phenylmethyl)carbamyl] nicotinic acid Rapamycin-42-ester with 3-l(phenylmethyl)carbamyl] picolinic acid Example 2 Rapamvcin 31~42-diester with ~oxo-4-r~2-(2-pvridinvl)ethvllaminolbutanoic acid To a solution of 5.0 g (50 mmol) of succinic anhydride in 50 mL of dichloromethane was added 550 mg of DMAP and 6.1 g (50 mmol) of 2-~2'-aminoethyl)pyridine. An exothermic reaction resulted. The reaction was refluxed for 1 h and cooled to room temp~rature and stirred for 48 h. The reaction is worked up by concentrated in vacuo: the ~esulting solid was dissolved in pH 4 buffer and extracted three times with 4: 1 ethyl acetate/tetrahydrofuran after the aqueous solution had been saturated with ammonium sulfate. The organic layer was dried over sodium sulfate and concentrated in vacuo to ~ive a residue. The residue was recrystallized from ethyl acetate/methanol to give 5.5 g (S0 %) of 4-oxo-4-[[2-(2-pyridinyl)ethyl]amino]butanoic acid.
To a solution of 3.8 g (4.19 mmol) of rapamycin in 125 mL of dichloromethane was added at room tempera~ure, 200 mg of DMAP,4.3 g (20.9 mmol) of dicyclohexyl-carbodiimide and 4.6 g (20.7 mmol) of 4-oxo-4-[[2-(2-pyridinyl)ethyl]amino]butanoic acid. The reaction was stirred overnight at room temperature. The reaction mixture was poured into water and extracted twice with ethyl acetate. The combined organic extracts were dried over sodium sullate and concentrated in vacuo to give a solid residue. The residue was purified by preparative HPLC (Waters Prep 501), 5 % methanol/ethyl ~X5~7 acetate) to give 4.30 g (79 %) of pure rapamycin 31,42-ester with 4-oxo-4-[[2-(2-pyridinyl)-ethyl]amino]butanoic acid.
The spectral data follows: lH NMR (CDC13, 400 MHz) o 8.53 (s, 1 H, arom), 7.67 (m, 1 H, arom), 7.22 (m, 2 H, arom), 6.74 (m, 1 H, arom), 4.63 (m, 1 H, -CHO2CCH2), 4.18 (m, 1 H, 31-CHOH), 3.68 (m, 2 H, -CONHCH2), 3.36 (s, 3 H, -OCH3), 3.35 (s, 3 H, -OCH3), 3.14 (s, 3 H, -OCH3), 3.02 (m, 2 H, CH2Pyr), 2.67 (s, 3 ~1, -02CCH2CH2CONHR), 1.75 (s, 3 H, CH3C=C-), 1.66 (s, 3 H, CH3C=C-);
IR (KBr) 3390 (OH), 2930, 2850, 1735 (C=O), 1640 (C=O), 1535, 1455, 1380, 1295, 1100, 995 cm-l; MS (neg. FAB) 1321 (M-).
The following representative compounds can be prepared from rapamycin and the appropriate arnido-ester by employing the method used to prepare the title compound in Example 2.
Rapamycin-31,42-diester with 4-[[1-(4-chlorophenyl)methyl]amino]-4-oxobutanoic acid Rapamycin-31,42-diester with 6-(N-methyl-N-hexylamino)-6-oxohexanoic acid Rapamycin-31,42-diester with 4-[[3-(dimethylamino)propyl]amino]-4Oxobutanoic acid Rapamycin-31,42-diester with 5-[[4-(octylamino)butyl]amino]-5-oxopentanoic acid Rapamycin-31,42-diester with 4-[[2-(3-(6-hydroxyquinolyl))ethyl]amino]-4-oxobutanoic acid Rapamycin-31,42-diester with 4-[[2-(phenylmethylamino)ethyl]amino]-4Oxobutanoic acid Rapamycin-31,42-diester with 4-[~2-(2-indolyl)ethyl]amino]-4-oxobutanoic acid Rapamycin-31,42-diester with 5-(N-hexyl-N-decylamino)-5-oxopentanoic acid Rapamycin-31,42-diester with 2-(dimethylcarbamyl) benzoic acid Rapamycin-31,42-diester with 2-1[3-(diethylamino)propyl]carbamyl] benzoic acid Example 3 Rapamycin 31.42-diester with 4-oxo-4-ir2-(2-pYridinvl)ethvllaminol butanoic acid dihvdrochlorid~
To a solution of Sû0 mg (37811mol) of rapamycin 31,42-ester with 4-oxo-4-[[2-(2-pyridinyl)ethyl]amino]butanoic acid in 2 mL of methanol was added 5~ ',lL of acetyl chloride. The reaction mixture is concentrated in vacuo to give 530 mg (100 %) of pure 20~8a67 rapamycin 31,42-ester with 4-oxo-4-[[2-(2-pyridinyl3ethyl]amino]butanoic acid dihydrochloride .
The spec~al data follows: lH NMR (d6-DMSO, ~00 MHz) â 8.53 ~s, 1 H, arom), 8.32 (m, 1 H, arom), 7.76 (m, 2 H, arom), 8.06 (m, 1 H, arom), 3.45 (m, 5 H, -S OCH3 and -CONHCH2), 3.44 (s, 3 H, -OC1~3), 3.23 Is, 3 H, -OCH3), 3.07 (m, 2 H, CH2Pyr), 2.49 (s, 3 H, -O2CCH2CH2CONHR), 1.79 (s, 3 H, CH3C=C-), 1.66 (s, 3 H, CH3C=C-); IR (KBr) 3400 (OH), 2920, 2850, 1735 (C=O), 1635 (C=O), 1545, 144~, 1370, 1150, 985 cm~l; MS (neg. FAB) calculated for C73H113N5O17 1321.8950, found 1321.7350; MS (neg. FAB~ 1321 (free base, M-), 590, 446 (100), 297.
AnalysisCalcdforC73HIlsNsOl7Cl2 5H2O C 56.04; H 6.71; N 4.47 Found C 55.66; H 6.36; N 4.29 Example 4 .
Rapamvcin 31.42-diester with 2-r2-1 (3-carboxy- 1 -oxopropvl)aminolethyll - 1 -methyl-~yridinium iodide To a solution of 500 mg (378 llmol) of rapamycin 31,42-ester with 4-oxo-4-~[2-(2-pyridinyl)ethyl]amino]butanoic acid in 2 mL of acetone was added 50 ~lL of methyl iodide and the reaction was stirred overnight at room temperature. The reaction was incomplete so 25 ',lL of methyl iodide was added and refluxed. The reac~ion mixture was cooled to room temperature and concentrated in vacuo to give 580 mg (98 %) of rapamycin 31,42-ester with 2-[2-[(3-carboxy-1-oxopropyl)amino]ethyl]-1-methylpyridinium iodide, which was isolated as the tetrahydrate.
The spectral data follows: IH NMR (CDC13, 400 MHz) ~ 9.05 (m, 1 H, arom), 8.40 (m, 1 H, arom), 8.04 (m, 1 H, arom), 7.89 (m, 2 H, arom), 4.53 (s, 3 H, NCH3+), 3.64 (m, 2 H, -CONHCH2), 3.38 (s, 3 H, -OCH3), 3.33 (s, 3 H, -OCH3), 3.12 (s, 3 H, -OCH3), 3.09 (m, 2 H, CH2Pyr), 2.56 (s, 3 H, -02CCH2CH2CONHR), 1.82 (s, 3 H, CH3C=C-), 1.64 (s, 3 1~, CH3C=C-); IR (KBr) 3410 (OH), 2920, 2840, 1720 (C=O), 1625 (C=O), 1535, 1430, 1360, 1225, 1100, 985 cm-l; MS (neg. FAB) 1605 (M-)-AnalysisCalcdfor('7sHIogNsol7I2 4H2O C 53.67; H 6.97; N 4.17 Found C 53.96; H 6.83; N 3.72 ,~ 2068~g7 The following representative compounds can be prepared from an appropriately substituted rapamycin ester and an appropriately substituted alkylating agent byemploying the method used tO prepare the title compound in Example 4.
S Rapamycin-3 1 ,42-diester with 3-[(3-carboxy- 1 -oxopropyl)amino]propyl trimethyl ammonium iodide Rapamycin-31,42-diester with 3-[(3-carboxy-1-oxopropyl)amino]propyl trimethyl ammonium sulfate Rapamycin-3 1 ,42-diester wi th 3-[(3-carboxy- 1 -oxopropyl)amino]propyl trimethyl ammonium phosphate Rapamycin-31,42-diester with 3-[(3-carboxy-1-oxopropyl)amino]propyl trimethyl ammonium p-toluenesulfonate Rapamycin-31,42-diester with 3-[2-[(3-carboxy-1-oxopropyl)amino]ethyl]-1-methyl-quinolinium iodide~
Claims (10)
1. A compound of the structure wherein R1 and R2 are each independently, hydrogen or ;
X is -(CH2)m- or -Ar-;
R3 and R4 are each, independently, hydrogen, alkyl of 1-12 carbon atoms, -(CH2)n-Ar, -(CH2)p-NR5R6, or -(CH2)p-N+R5R6R7Y-;
R5 and R6 are each, independently, hydrogen, alkyl of 1-12 carbon atoms, or -(CH2)n-Ar;
Ar is an optionally mono- or di- substituted group selected from , , , , , ,or in which the optional substituents are selected from the group consisting of alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, or perfluoroalkyl of 1-6 carbon atoms;
R7 is alkyl of 1-6 carbon atoms;
Y is a halide, sulfate, phosphate, or p-toluenesulfonate anion;
m= 1-6;
n= 1-6;
p = 1-6;
with the proviso that R1 and R2 are not both hydrogen;
or a pharmaceutically acceptable salt thereof.
X is -(CH2)m- or -Ar-;
R3 and R4 are each, independently, hydrogen, alkyl of 1-12 carbon atoms, -(CH2)n-Ar, -(CH2)p-NR5R6, or -(CH2)p-N+R5R6R7Y-;
R5 and R6 are each, independently, hydrogen, alkyl of 1-12 carbon atoms, or -(CH2)n-Ar;
Ar is an optionally mono- or di- substituted group selected from , , , , , ,or in which the optional substituents are selected from the group consisting of alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, or perfluoroalkyl of 1-6 carbon atoms;
R7 is alkyl of 1-6 carbon atoms;
Y is a halide, sulfate, phosphate, or p-toluenesulfonate anion;
m= 1-6;
n= 1-6;
p = 1-6;
with the proviso that R1 and R2 are not both hydrogen;
or a pharmaceutically acceptable salt thereof.
2. A compound according to Claim 1 in which X is -(CH2)m-.
3. A compound according to Claim 1 in which X is -(CH2)m- and R3 and R4 are alkyl of 1-6 carbon atoms.
4. A compound according to Claim 1 in which X is -(CH2)m-, R3 is hydrogen, and R4 is and Ar is -(CH2)n-Ar.
5. A compound according to Claim 1 which is rapamycin 42-ester with 4-(dimethylamino)-4-oxobutanoic acid.
6. A compound according to Claim 1 which is rapamycin 31,42-diester with 4-oxo-4-[[2-(2-pyridinyl)ethy]]amino]butanoic acid or a pharmaceutically acceptable salt thereof.
7. A compound according to Claim 6 which is rapamycin 31,42-diester with 4-oxo-4-[[2-(2-pyridinyl)ethyl]amino]butanoic acid dihydrochloride.
8. A compound according to claim 1 which is rapamycin 31,42-diester with 2-[2-[(3-carboxy-1-oxopropyl)amino]ethyl]-1-methyl-pyridinium iodide.
9. A method of treating transplantation rejection, host vs. draft disease, autoimmune diseases, and diseases of inflammation in a mammal by administering an effective amount of a compound having the structure wherein R1 and R2 are each independently, hydrogen or ;
X is -(CH2)m- or -Ar-;
R3 and R4 are each, independently, hydrogen, alkyl of 1-12 carbon atoms, -(CH2)n-Ar, -(CH2)p-NRSR6, or -(CH2)p-N+RSR6R7Y-;
R5 and R6 are each, independently, hydrogen, alkyl of 1-12 carbon atoms, or -(CH2)n-Ar;
Ar is an optionally mono- or di- substituted group selected from , , , , , ,or in which the optional substituents are selected from the group consisting of alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, or perfluoroalkyl of 1-6 carbon atoms;
R7 is alkyl of 1-6 carbon atoms;
Y is a halide, sulfate, phosphate, or p-toluenesulfonate anion;
m= 1-6;
n= 1-6;
p= 1-6;
with the proviso that R1 and R2 are not both hydrogen;
or a pharmaceutically acceptable salt thereof.
X is -(CH2)m- or -Ar-;
R3 and R4 are each, independently, hydrogen, alkyl of 1-12 carbon atoms, -(CH2)n-Ar, -(CH2)p-NRSR6, or -(CH2)p-N+RSR6R7Y-;
R5 and R6 are each, independently, hydrogen, alkyl of 1-12 carbon atoms, or -(CH2)n-Ar;
Ar is an optionally mono- or di- substituted group selected from , , , , , ,or in which the optional substituents are selected from the group consisting of alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, or perfluoroalkyl of 1-6 carbon atoms;
R7 is alkyl of 1-6 carbon atoms;
Y is a halide, sulfate, phosphate, or p-toluenesulfonate anion;
m= 1-6;
n= 1-6;
p= 1-6;
with the proviso that R1 and R2 are not both hydrogen;
or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising an immunosuppressive amount of a compound of claim 1 and a pharmaceutical carrier.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US703,240 | 1991-05-20 | ||
| US07/703,240 US5118677A (en) | 1991-05-20 | 1991-05-20 | Amide esters of rapamycin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2068567A1 true CA2068567A1 (en) | 1992-11-21 |
Family
ID=24824606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002068567A Abandoned CA2068567A1 (en) | 1991-05-20 | 1992-05-13 | Amide esters of rapamycin |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5118677A (en) |
| EP (1) | EP0515140A1 (en) |
| JP (1) | JPH05148271A (en) |
| KR (1) | KR920021554A (en) |
| AU (1) | AU641319B2 (en) |
| CA (1) | CA2068567A1 (en) |
| CZ (1) | CZ145792A3 (en) |
| FI (1) | FI922201A (en) |
| HU (1) | HUT62590A (en) |
| MX (1) | MX9202285A (en) |
| NO (1) | NO921976L (en) |
| NZ (1) | NZ242778A (en) |
| SK (1) | SK145792A3 (en) |
| ZA (1) | ZA923601B (en) |
Families Citing this family (217)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
| FI921595A (en) * | 1991-04-17 | 1992-10-18 | American Home Prod | RAPAMYCINKARBAMATER |
| US5565560A (en) * | 1991-05-13 | 1996-10-15 | Merck & Co., Inc. | O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
| US5247076A (en) * | 1991-09-09 | 1993-09-21 | Merck & Co., Inc. | Imidazolidyl macrolides having immunosuppressive activity |
| US5252732A (en) * | 1991-09-09 | 1993-10-12 | Merck & Co., Inc. | D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity |
| US5177203A (en) * | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| ZA935111B (en) * | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
| ZA935112B (en) * | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5256790A (en) * | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| US5480989A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5489680A (en) * | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
| US5434260A (en) * | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
| ATE321053T1 (en) * | 1992-10-13 | 2006-04-15 | Wyeth Corp | CARBAMATES OF RAPAMYCIN |
| US5302584A (en) * | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| US5480988A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5262423A (en) * | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
| US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| US5260300A (en) | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
| US5349060A (en) * | 1993-01-07 | 1994-09-20 | American Home Products Corporation | Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents |
| US5252579A (en) * | 1993-02-16 | 1993-10-12 | American Home Products Corporation | Macrocyclic immunomodulators |
| US5310901A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives |
| US5310903A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
| GB9307491D0 (en) | 1993-04-08 | 1993-06-02 | Sandoz Ltd | Organic compounds |
| USRE40596E1 (en) * | 1993-04-08 | 2008-12-02 | Novartis Ag | Rapamycin assay |
| US5504091A (en) * | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
| US7279561B1 (en) * | 1993-04-23 | 2007-10-09 | Wyeth | Anti-rapamycin monoclonal antibodies |
| JPH08509499A (en) | 1993-04-23 | 1996-10-08 | アボツト・ラボラトリーズ | Rapamycin conjugates and antibodies |
| USRE37421E1 (en) | 1993-07-16 | 2001-10-23 | Smithkline Beecham Corporation | Rapamycin derivatives |
| US5387680A (en) * | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
| US5373014A (en) * | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
| US5391730A (en) * | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
| US5378836A (en) * | 1993-10-08 | 1995-01-03 | American Home Products Corporation | Rapamycin oximes and hydrazones |
| EP0729471A1 (en) * | 1993-11-19 | 1996-09-04 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| US5527907A (en) * | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
| US5385910A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
| US5385909A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
| US5385908A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
| DE69423781T2 (en) * | 1993-12-17 | 2000-08-10 | Novartis Ag | RAPAMYCIN DERIVATIVES AS IMMUNO SUPPRESSORS |
| US5389639A (en) * | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
| US5525610A (en) * | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5463048A (en) * | 1994-06-14 | 1995-10-31 | American Home Products Corporation | Rapamycin amidino carbamates |
| US5693648A (en) * | 1994-09-30 | 1997-12-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity |
| IL129547A (en) | 1994-10-26 | 2001-01-11 | Novartis Ag | Pharmaceutical compositions comprising a macrolide and an acid |
| US5491231A (en) * | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
| US5563145A (en) * | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
| DE69624921T2 (en) * | 1995-06-09 | 2003-09-11 | Novartis Ag | rapamycin derivatives |
| US5780462A (en) * | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| US5922730A (en) * | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
| US20030216303A1 (en) * | 1998-03-06 | 2003-11-20 | Michael Ambuhl | Emulsion preconcentrates containing cyclosporin or a macrolide |
| US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2000041698A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| US6331547B1 (en) | 1999-08-18 | 2001-12-18 | American Home Products Corporation | Water soluble SDZ RAD esters |
| US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
| US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
| US6790228B2 (en) * | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
| US6277983B1 (en) | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
| GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| US6670355B2 (en) | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
| DK1318837T3 (en) | 2000-08-11 | 2005-01-10 | Wyeth Corp | Method of treating estrogen receptor positive carcinoma |
| WO2002024706A2 (en) | 2000-09-19 | 2002-03-28 | Wyeth | Water soluble rapamycin esters |
| US6399625B1 (en) | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
| US6399626B1 (en) | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
| US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| IL162734A0 (en) | 2002-02-01 | 2005-11-20 | Ariad Gene Therapeutics Inc | Phosphorus-containing compounds & uses thereof |
| AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
| PT1553940E (en) | 2002-07-30 | 2008-05-09 | Wyeth Corp | Parenteral formulations containing a rapamycin hydroxyester |
| AR042942A1 (en) | 2003-01-27 | 2005-07-06 | Endocyte Inc | CONJUGATES OF DRUG ADMINISTRATION OF VITAMIN RECEPTORS UNION |
| UY28213A1 (en) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | NEW CYANOPIRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS. |
| DE602004007382T2 (en) | 2003-05-20 | 2008-04-17 | Bayer Pharmaceuticals Corp., West Haven | DIARYL UREAS FOR PDGFR MEDIATED DISEASES |
| US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
| DE602004010407T2 (en) * | 2003-07-23 | 2008-10-16 | Bayer Pharmaceuticals Corp., West Haven | FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYL-UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND SUFFERING |
| EP1737869A1 (en) | 2004-04-14 | 2007-01-03 | Wyeth a Corporation of the State of Delaware | Regiospecific synthesis of rapamycin 42-ester derivatives |
| CN1946852A (en) * | 2004-04-27 | 2007-04-11 | 惠氏公司 | Labeling of rapamycin using rapamycin-specific methylases |
| WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
| US8288557B2 (en) | 2004-07-23 | 2012-10-16 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
| CA2581372A1 (en) * | 2004-09-30 | 2006-04-13 | Ariad Gene Therapeutics, Inc. | Treatment method |
| MX2007003789A (en) * | 2004-10-04 | 2007-07-20 | Qlt Usa Inc | Ocular delivery of polymeric delivery formulations. |
| US8313763B2 (en) * | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| WO2006050461A1 (en) * | 2004-10-28 | 2006-05-11 | Wyeth | Use of an mtor inhibitor in treatment of uterine leiomyoma |
| US8021849B2 (en) * | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
| GB0503936D0 (en) | 2005-02-25 | 2005-04-06 | San Raffaele Centro Fond | Method |
| US8044200B2 (en) * | 2005-03-16 | 2011-10-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
| US7189582B2 (en) * | 2005-04-27 | 2007-03-13 | Dade Behring Inc. | Compositions and methods for detection of sirolimus |
| EP1886138A4 (en) * | 2005-05-11 | 2009-04-15 | Genetic Technologies Ltd | Methods of enriching fetal cells |
| MX2008000897A (en) | 2005-07-20 | 2008-03-18 | Novartis Ag | Combination of a pyrimidylaminobenzamide and an mtor kinase inhibitor. |
| PL1912675T3 (en) | 2005-07-25 | 2014-10-31 | Emergent Product Dev Seattle | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| KR20130113543A (en) * | 2005-08-19 | 2013-10-15 | 엔도사이트, 인코포레이티드 | Multi-drug ligand conjugates |
| PE20070763A1 (en) | 2005-11-04 | 2007-08-08 | Wyeth Corp | ANTINEOPLASTIC COMBINATIONS OF AN INHIBITOR OF mTOR, TRASTUZUMAB AND / OR HKI-272 |
| KR20080077989A (en) * | 2005-12-20 | 2008-08-26 | 와이어쓰 | Control of cci-779 dosage form stability through control of drug substance impurities |
| US20070196850A1 (en) * | 2006-01-27 | 2007-08-23 | University Of Washington | Identification of aging genes through large-scale analysis |
| US20080051691A1 (en) * | 2006-08-28 | 2008-02-28 | Wyeth | Implantable shunt or catheter enabling gradual delivery of therapeutic agents |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| EP2481427A1 (en) | 2007-03-14 | 2012-08-01 | Endocyte, Inc. | Folate-Tubulysin conjugates |
| TW200901989A (en) | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
| JP2008305262A (en) * | 2007-06-08 | 2008-12-18 | Konica Minolta Business Technologies Inc | Printer introduction method in server and thin client environment |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| RU2523909C2 (en) | 2007-06-25 | 2014-07-27 | Эндосайт, Инк. | Conjugates, containing hydrophilic spacers of linkers |
| AU2008287195A1 (en) * | 2007-07-06 | 2009-02-19 | Emergent Product Development Seattle, Llc | Binding peptides having a C-terminally disposed specific binding domain |
| US20100048914A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| AU2009225434B2 (en) * | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| US20090253733A1 (en) * | 2008-04-02 | 2009-10-08 | Biointeractions, Ltd. | Rapamycin carbonate esters |
| WO2009126944A1 (en) | 2008-04-11 | 2009-10-15 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| CA2743491C (en) | 2008-11-11 | 2016-10-11 | Zelton Dave Sharp | Inhibition of mammalian target of rapamycin |
| EP3023433A1 (en) | 2009-02-05 | 2016-05-25 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| EP2493460A4 (en) | 2009-10-30 | 2013-04-24 | Ariad Pharma Inc | Methods and compositions for treating cancer |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| EA201290876A1 (en) | 2010-03-05 | 2013-03-29 | Президент Энд Феллоуз Оф Гарвард Колледж | COMPOSITIONS OF INDUCED DENDRITIC CELLS AND THEIR USE |
| ES2689177T3 (en) | 2010-04-13 | 2018-11-08 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 inhibitor or cyclin dependent kinase (CDK4 / 6) and an mTOR inhibitor for treating cancer |
| EP2558082A1 (en) | 2010-04-16 | 2013-02-20 | Novartis AG | Combination of organic compounds |
| WO2011134899A1 (en) | 2010-04-27 | 2011-11-03 | Roche Glycart Ag | Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor |
| US9987356B2 (en) | 2011-03-11 | 2018-06-05 | Beth Israel Deaconess Medical Center, Inc. | Anti-CD40 antibodies and methods of administering thereof |
| EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| EA025948B1 (en) | 2011-04-25 | 2017-02-28 | Новартис Аг | COMBINATION OF A PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR AND A mTOR INHIBITOR |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| WO2013013708A1 (en) | 2011-07-26 | 2013-01-31 | Fundació Institut D'investigació Biomèdica De Bellvitge | Treatment of acute rejection in renal transplant |
| US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| US9408884B2 (en) | 2012-06-08 | 2016-08-09 | Biotronik Ag | Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods |
| WO2013192367A1 (en) | 2012-06-22 | 2013-12-27 | Novartis Ag | Neuroendocrine tumor treatment |
| EP2906214A1 (en) | 2012-10-12 | 2015-08-19 | The Board of Regents of The University of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
| CA2887727A1 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
| EP2914260A1 (en) | 2012-10-31 | 2015-09-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
| WO2014078522A1 (en) | 2012-11-14 | 2014-05-22 | Ohio State Innovation Foundation | Materials and methods useful for treating glioblastoma |
| WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| US9884067B2 (en) | 2013-03-14 | 2018-02-06 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
| WO2015023710A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| AU2014373683B2 (en) | 2013-12-31 | 2020-05-07 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| BR112016014903A8 (en) | 2014-02-11 | 2018-05-02 | Novartis Ag | pharmaceutical combinations comprising a pi3k inhibitor, its use, its combined preparation, and commercial packaging |
| AU2015237200A1 (en) | 2014-03-27 | 2016-10-06 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
| EP3131546B1 (en) | 2014-04-16 | 2022-02-16 | Rapamycin Holdings, Inc. | Oral rapamycin preparation for use in treating feline chronic gingivo- stomatitis (fcgs) |
| WO2015171723A1 (en) | 2014-05-06 | 2015-11-12 | Research Development Foundation | Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy |
| WO2015187541A1 (en) | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
| CN105461738B (en) * | 2014-06-03 | 2019-03-08 | 中国人民解放军军事医学科学院毒物药物研究所 | A kind of rapamycin derivative, preparation method, its pharmaceutical composition and purposes |
| WO2016040806A1 (en) | 2014-09-11 | 2016-03-17 | The Regents Of The University Of California | mTORC1 INHIBITORS |
| WO2017029391A1 (en) | 2015-08-20 | 2017-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating cancer |
| EP3307322B1 (en) | 2015-09-04 | 2021-02-17 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
| EP3466424A1 (en) | 2016-05-27 | 2019-04-10 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprizing rapamycin or derivative thereof |
| KR20230150408A (en) | 2016-12-22 | 2023-10-30 | 암젠 인크 | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| US20210154372A1 (en) | 2017-05-15 | 2021-05-27 | C.R. Bard, Inc. | Medical device with drug-eluting coating and intermediate layer |
| JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| EP3644997A1 (en) | 2017-06-26 | 2020-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of olmsted syndrome |
| EP3652306A1 (en) | 2017-07-13 | 2020-05-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/-tregs |
| TWI731264B (en) | 2017-09-08 | 2021-06-21 | 美商安進公司 | Inhibitors of kras g12c and methods of using the same |
| JP7381492B2 (en) | 2018-05-01 | 2023-11-15 | レヴォリューション・メディスンズ，インコーポレイテッド | C26-linked rapamycin analogs as MTOR inhibitors |
| CR20200578A (en) | 2018-05-01 | 2021-02-22 | Revolution Medicines Inc | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors |
| JP7266043B2 (en) | 2018-05-04 | 2023-04-27 | アムジエン・インコーポレーテツド | KRas G12C inhibitors and methods of using them |
| CA3099118A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| MA52564A (en) | 2018-05-10 | 2021-03-17 | Amgen Inc | KRAS G12C INHIBITORS FOR CANCER TREATMENT |
| JP7360396B2 (en) | 2018-06-01 | 2023-10-12 | アムジエン・インコーポレーテツド | KRAS G12C inhibitors and methods of using the same |
| MX2020012204A (en) | 2018-06-11 | 2021-03-31 | Amgen Inc | Kras g12c inhibitors for treating cancer. |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| CA3107352A1 (en) | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
| AU2019310039A1 (en) | 2018-07-23 | 2021-02-18 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
| EP3849545A1 (en) | 2018-09-10 | 2021-07-21 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of neurofibromatosis |
| JP7262581B2 (en) | 2018-11-14 | 2023-04-21 | ルトニックス，インコーポレーテッド | Medical device with drug eluting coating on modified device surface |
| JP2020090482A (en) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediate of kras g12c inhibitor compound |
| MA55136A (en) | 2018-11-19 | 2022-02-23 | Amgen Inc | G12C KRAS INHIBITORS AND METHODS OF USE THEREOF |
| JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
| MX2021007158A (en) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors. |
| MX2021007157A (en) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors. |
| MA54550A (en) | 2018-12-20 | 2022-03-30 | Amgen Inc | KIF18A INHIBITORS |
| BR112021011989A2 (en) | 2018-12-20 | 2021-09-08 | Amgen Inc. | KIF18A INHIBITORS |
| CA3130083A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| JP2022522777A (en) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | Bicyclic heteroaryl compounds and their use |
| WO2020209828A1 (en) | 2019-04-08 | 2020-10-15 | Bard Peripheral Vascular, Inc. | Medical device with drug-eluting coating on modified device surface |
| KR20220011123A (en) | 2019-04-11 | 2022-01-27 | 엔클리어 테라피스, 인크. | Cerebrospinal fluid improvement method and device and system therefor |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| JP7092935B2 (en) | 2019-05-21 | 2022-06-28 | アムジエン・インコーポレーテツド | Solid form |
| CN114401953A (en) | 2019-08-02 | 2022-04-26 | 美国安进公司 | KIF18A inhibitors |
| WO2021026098A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| EP4007638A1 (en) | 2019-08-02 | 2022-06-08 | Amgen Inc. | Pyridine derivatives as kif18a inhibitors |
| US20220281843A1 (en) | 2019-08-02 | 2022-09-08 | Amgen Inc. | Kif18a inhibitors |
| JP2022552873A (en) | 2019-10-24 | 2022-12-20 | アムジエン・インコーポレーテツド | Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer |
| MX2022005053A (en) | 2019-10-28 | 2022-05-18 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12c mutant. |
| JP2023515235A (en) | 2019-10-31 | 2023-04-12 | 大鵬薬品工業株式会社 | 4-aminobut-2-enamide derivatives and salts thereof |
| US11608346B2 (en) | 2019-11-04 | 2023-03-21 | Revolution Medicines, Inc. | Ras inhibitors |
| JP2022553858A (en) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | RAS inhibitor |
| CA3159559A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| JP2023500328A (en) | 2019-11-08 | 2023-01-05 | レボリューション メディシンズ インコーポレイテッド | Bicyclic heteroaryl compound and use thereof |
| TW202132271A (en) | 2019-11-14 | 2021-09-01 | 美商安進公司 | Improved synthesis of kras g12c inhibitor compound |
| BR112022009390A2 (en) | 2019-11-14 | 2022-08-09 | Amgen Inc | IMPROVED SYNTHESIS OF KRAS INHIBITOR COMPOUND G12C |
| JP2023505100A (en) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | Covalent RAS inhibitors and uses thereof |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| JP2023509701A (en) | 2020-01-07 | 2023-03-09 | レヴォリューション・メディスンズ，インコーポレイテッド | SHP2 inhibitor dosing and methods of treating cancer |
| EP4139299A1 (en) | 2020-04-24 | 2023-03-01 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| WO2021215545A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
| WO2022014640A1 (en) | 2020-07-15 | 2022-01-20 | 大鵬薬品工業株式会社 | Pyrimidine compound-containing combination to be used in tumor treatment |
| MX2023002248A (en) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Use of sos1 inhibitors to treat malignancies with shp2 mutations. |
| CR20230165A (en) | 2020-09-15 | 2023-06-02 | Revolution Medicines Inc | Indole derivatives as ras inhibitors in the treatment of cancer |
| EP4267250A1 (en) | 2020-12-22 | 2023-11-01 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| BR112023022819A2 (en) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | COMPOUNDS, PHARMACEUTICAL COMPOSITION, CONJUGATES AND METHODS FOR TREATING CANCER IN A SUBJECT, FOR TREATING A DISORDER AND FOR INHIBITING A RAS PROTEIN IN A CELL |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CN117616031A (en) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | RAS inhibitors for the treatment of cancer |
| WO2022250170A1 (en) | 2021-05-28 | 2022-12-01 | Taiho Pharmaceutical Co., Ltd. | Small molecule inhibitors of kras mutated proteins |
| CA3223081A1 (en) | 2021-07-15 | 2023-01-19 | Samir Mitragotri | Compositions and methods relating to cells with adhered particles |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024008799A1 (en) | 2022-07-06 | 2024-01-11 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of proliferative glomerulonephritis |
| WO2024028433A1 (en) | 2022-08-04 | 2024-02-08 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of lymphoproliferative disorders |
| WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) * | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
| US4316885A (en) * | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US4650803A (en) * | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| JPH04230389A (en) * | 1990-07-16 | 1992-08-19 | American Home Prod Corp | Rapamycin derivative |
| FI921595A (en) * | 1991-04-17 | 1992-10-18 | American Home Prod | RAPAMYCINKARBAMATER |
| JP3108192B2 (en) * | 1991-05-07 | 2000-11-13 | アメリカン・ホーム・プロダクツ・コーポレイション | Reduction products of rapamycin for immunosuppressive, anti-inflammatory or antifungal agents |
-
1991
- 1991-05-20 US US07/703,240 patent/US5118677A/en not_active Expired - Lifetime
-
1992
- 1992-05-13 CA CA002068567A patent/CA2068567A1/en not_active Abandoned
- 1992-05-13 JP JP4120365A patent/JPH05148271A/en active Pending
- 1992-05-14 FI FI922201A patent/FI922201A/en not_active Application Discontinuation
- 1992-05-14 SK SK1457-92A patent/SK145792A3/en unknown
- 1992-05-14 CZ CS921457A patent/CZ145792A3/en unknown
- 1992-05-15 KR KR1019920008231A patent/KR920021554A/en not_active Application Discontinuation
- 1992-05-15 MX MX9202285A patent/MX9202285A/en unknown
- 1992-05-15 HU HU9201622A patent/HUT62590A/en unknown
- 1992-05-18 NZ NZ24277892A patent/NZ242778A/en unknown
- 1992-05-18 ZA ZA923601A patent/ZA923601B/en unknown
- 1992-05-19 NO NO92921976A patent/NO921976L/en unknown
- 1992-05-19 EP EP19920304522 patent/EP0515140A1/en not_active Withdrawn
- 1992-05-19 AU AU16378/92A patent/AU641319B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX9202285A (en) | 1992-11-01 |
| US5118677A (en) | 1992-06-02 |
| NZ242778A (en) | 1994-07-26 |
| NO921976L (en) | 1992-11-23 |
| NO921976D0 (en) | 1992-05-19 |
| CZ145792A3 (en) | 1993-01-13 |
| AU641319B2 (en) | 1993-09-16 |
| KR920021554A (en) | 1992-12-18 |
| JPH05148271A (en) | 1993-06-15 |
| FI922201A0 (en) | 1992-05-14 |
| SK145792A3 (en) | 1995-04-12 |
| AU1637892A (en) | 1992-11-26 |
| HU9201622D0 (en) | 1992-08-28 |
| EP0515140A1 (en) | 1992-11-25 |
| ZA923601B (en) | 1993-11-18 |
| FI922201A (en) | 1992-11-21 |
| HUT62590A (en) | 1993-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2068567A1 (en) | Amide esters of rapamycin | |
| US5118678A (en) | Carbamates of rapamycin | |
| US5130307A (en) | Aminoesters of rapamycin | |
| AU653175B2 (en) | Carboxylic acid esters of rapamycin | |
| US5221670A (en) | Rapamycin esters | |
| US5162333A (en) | Aminodiesters of rapamycin | |
| EP0666861B1 (en) | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents | |
| US5120726A (en) | Rapamycin hydrazones | |
| US5378696A (en) | Rapamycin esters | |
| CA2086643C (en) | Oxepane isomers of rapamycin useful as immunosuppressive agents | |
| US5346893A (en) | Rapamycin 42-sulfonates and 42-(N-carbalkoxy) sulfamates useful as immunosuppressive agents | |
| US5302600A (en) | 27-hydroxyrapamycin and derivatives thereof | |
| US5446048A (en) | Rapamycin oximes | |
| US5672605A (en) | Macrolide immunomodulators | |
| US5358944A (en) | Rapamycin esters for treating transplantation rejection | |
| EP0467606A1 (en) | Rapamycin derivatives | |
| JPH05163280A (en) | Bicyclic rapamycin | |
| US5260299A (en) | Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents | |
| US5416086A (en) | Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents | |
| WO1998009972A1 (en) | Rapamycin derivatives with unnatural stereochemistries | |
| EP0655065B1 (en) | 27-hydroxyrapamycin and derivatives thereof | |
| CN107827908B (en) | Rapamycin triazole derivative and preparation method and application thereof | |
| WO1993018043A1 (en) | Novel rapamycin 42-sulfonates and 42-(n-carboalkoxy)sulfamates useful as immunosuppressive agents | |
| IE921606A1 (en) | Amide esters of rapamycin | |
| NZ239852A (en) | Esters of rapamycin and pharmaceutical and fungicidal composition thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |